These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 2296267)
21. [Drug therapy of child behavior disorders]. Corboz RJ Wien Med Wochenschr; 1969 Jul; 119(30):540-7. PubMed ID: 5351661 [No Abstract] [Full Text] [Related]
22. Reserpine therapy of phenothiazine induced dyskinesia. Sato S; Daly R; Peters H Dis Nerv Syst; 1971 Oct; 32(10):680-5. PubMed ID: 5146426 [No Abstract] [Full Text] [Related]
23. Multiple rhythmic movement disorders in a teenage boy with excellent response to clonazepam. Janković SM; Sokić DV; Vojvodić NM; Ristić AJ; Kostić VS Mov Disord; 2008 Apr; 23(5):767-8. PubMed ID: 18307267 [No Abstract] [Full Text] [Related]
24. [New chemical substances usable in therapy]. Clin Ter; 1966 Jun; 37(5):467-9. PubMed ID: 6011334 [No Abstract] [Full Text] [Related]
25. [Botulinum toxin therapy: from dreaded biological toxin to standard pharmaceutical]. Schnider P; Voller B; Moraru K; Auff E Wien Klin Wochenschr; 1999 Oct; 111(20):825-9. PubMed ID: 10586486 [No Abstract] [Full Text] [Related]
26. [The role of endorphines in regulation of pain sensitivity]. Maslov LN; Lishmanov IuB; Terashvili M; Malkova NV Patol Fiziol Eksp Ter; 2005; (1):27-9. PubMed ID: 15801238 [No Abstract] [Full Text] [Related]
27. Estrogen and movement disorders. Kompoliti K Clin Neuropharmacol; 1999; 22(6):318-26. PubMed ID: 10626091 [TBL] [Abstract][Full Text] [Related]
28. [Tremor and abnormal movement in multiple sclerosis: symptomatic therapeutic indications]. Viallet F; Witjas T; Gayraud D; Pelletier J; Regis J Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1079-84. PubMed ID: 11787340 [TBL] [Abstract][Full Text] [Related]
29. [Influence of chloroquine and hydroxychloroquine on the evolution of postischemic movement disorders]. Rosner I; Malhie P Therapie; 1967; 22(2):345-54. PubMed ID: 6063421 [No Abstract] [Full Text] [Related]
30. [Treatment of schizophrenic psychoses with gamma-type endorphins]. van Praag HM; Verhoeven WM; van Ree JM; de Wied D Ned Tijdschr Geneeskd; 1981 Nov; 125(48):1963-9. PubMed ID: 6171738 [No Abstract] [Full Text] [Related]
31. Anticipating the response to amphetamine therapy in the treatment of hyperkinetic children. Corad WG; Insel J Pediatrics; 1967 Jul; 40(1):96-9. PubMed ID: 6028905 [No Abstract] [Full Text] [Related]
32. [Considerations on the effects of propericiazine in psychomotor disorders. (Preliminary note)]. Pariante F; Scala A Osp Psichiatr; 1966; 34(3):435-46. PubMed ID: 4386035 [No Abstract] [Full Text] [Related]
33. [Lars Terenius about neuropeptides and pain: Endorphines alleviate stress--a curative effect? A new spinal-active analgesic insight. Interview by Birgit Lindell]. Terenius L Nord Med; 1985; 100(3):76-80. PubMed ID: 2581228 [No Abstract] [Full Text] [Related]
34. [Therapy of extrapyramidal-motor symptoms. Drug treatment]. Hartmann-von Monakow K Bibl Psychiatr Neurol; 1969; 139():697-704. PubMed ID: 5406928 [No Abstract] [Full Text] [Related]
35. [Antipsychotic efficacy of neuroleptic neuropeptides in schizophrenia. Review of clinical data]. Verhoeven VM Encephale; 1987; 13(6):349-56. PubMed ID: 2453339 [TBL] [Abstract][Full Text] [Related]